Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 125-129

  Alipour, Arash ^a   Cabezas, Manuel Castro ^a   Elte, Jan Willem F ^a   Vallvé, Joan Carles ^b   Ribalta, Josep ^b   Zwinderman, Aeilko H ^c,d,e   Defesche, Joep C ^f   Jukema, J Wouter ^d,e,g  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^e Durrer Center for Cardiogenetic Research   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coronary atherosclerosis; Mannose binding lectin; Pravastatin

Indexed keywords

MANNOSE BINDING LECTIN 2; PLACEBO; PRAVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DNA POLYMORPHISM; EXON; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; POLYMORPHISM, GENETIC; PRAVASTATIN;

EID: 79952100208     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.041     Document Type: Article

References (32)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Danesh J.P., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and update meta-analysis. BMJ 2000, 321:199-204.
3. Madsen H.O., Videm V., Svejgaard A., Svennevig J.L., Garred P. Association of mannose-binding lectin deficiency with severe atherosclerosis. Lancet 1998, 352:959-960.
4. Best L.G., Davidson M., North K.E., et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians. Circulation 2004, 109:471-475.
5. Hegele R.A., Ban M.R., Anderson C.M., Spence J.D. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Invest Med 2000, 48:198-202.
6. Ohlenschlaeger T., Garred P., Madsen H.O., Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004, 351:260-267.
7. Biezeveld M.H., Kuipers I.M., Geissler J., et al. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 2003, 361:1268-1270.
8. Fiane A.E., Ueland T., Simonsen S., et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J 2005, 26:1660-1665.
9. Alipour A., van Oostrom AJHHM, Van Wijk J.P.H., et al. Mannose binding lectin deficiency and triglyceride-rich lipoprotein metabolism in normolipidemic subjects. Atherosclerosis 2009, 206:444-450.
10. Walport J.W. Complement; first of two parts. N Engl J Med 2001, 344:1058-1065.
11. Turner M.W. The role of mannose-binding lectin in health and disease. Mol Immunol 2003, 40:423-429.
12. Madsen H.O., Garred P., Thiel S., et al. Interplay between promotor and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995, 155:3013-3020.
13. Crosdale D.J., Ollier W.E., Thomson W., et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. Eur J Immunogenet 2000, 27:111-117.
14. Salimans M.M., Bax W.A., Stegemans F., van Deuren M., Bartelink A.K., van Dijk H. Association between familial deficiency of mannose-binding lectin and mutations in the corresponding gene and promoter region. Clin Diagn Lab Immun 2004, 11:806-807.
15. Aittoniemi J., Fan Y.M., Laaksonen R., et al. The effect of mannan-binding lectin variant alleles on coronary artery reactivity in healthy young men. Int J Cardiol 2004, 97:317-318.
16. Hansen T.K., Tarnow L., Thiel S., et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004, 53:1570-1576.
17. Keller T.T., van Leuven S.I., Meuwese M.C., et al. Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol 2006, 26:2345-2350.
18. Rugonfalvi-Kiss S., Dósa E., Madsen H.O., et al. High rate of early restenosis after cartotid eversion endarteriectomy in homozygous carriers of the normal mannose-binding lectin deficiency. Stroke 2005, 36:944-948.
19. Collard C.D., Shernan S.K., Fox A.A., et al. The MBL2 'LYQA secretor' haplotype is an independent predictor of postoperative myocardial infarction in whites undergoing coronary artery bypass graft surgery. Circulation 2007, 116(11 Suppl.):I106-112.
20. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540. On behalf of the REGRESS Study Group, Interuniversity Cardiology Institute Utrecht, Netherlands.
21. LaRosa J.C., Grundy S.M., Waters D.D., et al. Treating to new targets (TNT) investigators, intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
22. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
23. Halkes C.J., van Dijk H., de Jaegere P.P., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001, 21:1526-1530.
24. Stephens M., Smith N., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
25. Souverein O.W., Zwinderman A.H., Tanck M.W. Estimating haplotype effects on dichotomous outcome for unphased genotype data using a weighted penalized log-likelihood approach. Hum Hered 2006, 61:104-110.
26. Muscari A., Bozzoli C., Puddu G.M., et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995, 98:357-364.
27. Verseyden C., Meijssen S., van Dijk H., Jansen H., Castro Cabezas M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 2003, 44:2100-2108.
28. Van Oostrom AJHHM, Alipour A., Plokker H.W.M., Sniderman A.D., Castro Cabezas M. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007, 90:167-173.
29. Muscari A., Massarelli G., Bastagli L., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000, 21:1081-1090.
30. Oksjoki R., Kovanen P.T., Pentikainen M.O. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003, 14:477-482.
31. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18:1386-1392.
32. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1740.